Adherence to drug-drug interaction alerts in high-risk patients: a trial of context-enhanced alerting

被引:47
|
作者
Duke, Jon D. [1 ,2 ]
Li, Xiaochun [3 ]
Dexter, Paul [1 ,2 ]
机构
[1] Regenstrief Inst Hlth Care, Dept Med Informat, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA
[3] Indiana Univ Sch Med, Div Biostat, Indianapolis, IN USA
关键词
CLINICAL DECISION-SUPPORT; PHYSICIAN ORDER ENTRY; MEDICATION SAFETY; SYSTEMS; FREQUENCY; CARE;
D O I
10.1136/amiajnl-2012-001073
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objective Drug-drug interaction (DDI) alerting is an important form of clinical decision support, yet physicians often fail to attend to critical DDI warnings due to alert fatigue. We previously described a model for highlighting patients at high risk of a DDI by enhancing alerts with relevant laboratory data. We sought to evaluate the effect of this model on alert adherence in high-risk patients. Methods A 6-month randomized controlled trial involving 1029 outpatient physicians was performed. The target interactions were all DDIs known to cause hyperkalemia. Alerts in the intervention group were enhanced with the patient's most recent potassium and creatinine levels. The control group received unmodified alerts. High -risk patients were those with baseline potassium >5.0 mEq/l and/or creatinine >= 1.5 mg/dl (132 mu mol/l). Results We found no significant difference in alert adherence in high-risk patients between the intervention group (15.3%) and the control group (16.8%) (p=0.71). Adherence in normal risk patients was significantly lower in the intervention group (14.6%) than in the control group (18.6%) (p<0.01). In neither group did physicians increase adherence in patients at high risk. Conclusions Physicians adhere poorly to hyperkalemia-associated DDI alerts even in patients with risk factors for a clinically significant interaction, and the display of relevant laboratory data in these alerts did not improve adherence levels in the outpatient setting. Further research is necessary to determine optimal strategies for conveying patient-specific DDI risk.
引用
收藏
页码:494 / 498
页数:5
相关论文
共 8 条
  • [1] Variation in high-priority drug-drug interaction alerts across institutions and electronic health records
    McEvoy, Dustin S.
    Sittig, Dean F.
    Hickman, Thu-Trang
    Aaron, Skye
    Ai, Angela
    Amato, Mary
    Bauer, David W.
    Fraser, Gregory M.
    Harper, Jeremy
    Kennemer, Angela
    Krall, Michael A.
    Lehmann, Christoph U.
    Malhotra, Sameer
    Murphy, Daniel R.
    O'Kelley, Brandi
    Samal, Lipika
    Schreiber, Richard
    Singh, Hardeep
    Thomas, Eric J.
    Vartian, Carl V.
    Westmorland, Jennifer
    Mccoy, Allison B.
    Wright, Adam
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2017, 24 (02) : 331 - 338
  • [2] The Effect of Patient-Specific Drug-Drug Interaction Alerting on the Frequency of Alerts: A Pilot Study
    Horn, John
    Ueng, Stephen
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (11) : 1087 - 1092
  • [3] Reliability, ease of use and usefulness of I-MeDeSA for evaluating drug-drug interaction alerts in an Australian context
    Baysari, Melissa T.
    Lowenstein, David
    Zheng, Wu Yi
    Day, Richard O.
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2018, 18
  • [4] Pilot evaluation of an optimized context-specific drug-drug interaction alerting system: A controlled pre-post study
    Cornu, Pieter
    Steurbaut, Stephane
    Gentens, Kristof
    Van de Velde, Rudi
    Dupont, Alain G.
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2015, 84 (09) : 617 - 629
  • [5] The effect of ICU-tailored drug-drug interaction alerts on medication prescribing and monitoring: protocol for a cluster randomized stepped-wedge trial
    Bakker, T.
    Klopotowska, J. E.
    Eslami, S.
    de Lange, D. W.
    van Marum, R.
    van der Sijs, H.
    de Jonge, E.
    Dongelmans, D. A.
    de Keizer, N. F.
    Abu-Hanna, A.
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2019, 19 (01)
  • [6] Added value of patient- and drug-related factors to stratify drug-drug interaction alerts for risk of QT prolongation: Development and validation of a risk prediction model
    Muylle, Katoo M. M.
    van Laere, Sven
    Pannone, Luigi
    Coenen, Samuel
    de Asmundis, Carlo
    Dupont, Alain G. G.
    Cornu, Pieter
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (04) : 1374 - 1385
  • [7] Randomised controlled decentralised feasibility trial of a fixed low-dose combination antihypertensive drug strategy to attenuate cognitive decline in high-risk adults
    Carcel, Cheryl
    Clancy, Lauren
    Harris, Katie
    Peters, Ruth
    Byrne, Aisling
    Bassett, Kimberley
    Freed, Ruth
    Hoyos, Camilla M.
    Rodgers, Anthony
    Lindley, Richard
    Chalmers, John
    Xu, Ying
    Woodward, Mark
    Ouyang, Menglu
    Naismith, Sharon L.
    Anderson, Craig
    BMJ OPEN, 2024, 14 (08):
  • [8] Interventions, Barriers, and Proposed Solutions Associated With the Implementation of a Protocol That Uses Clinical Decision Support and a Stress Biomarker Test to Identify ICU Patients at High-Risk for Drug Associated Acute Kidney Injury
    Williams, Victoria L.
    Smithburger, Pamela L.
    Imhoff, Allison N.
    Groetzinger, Lara M.
    Culley, Colleen M.
    Burke, Clayton X.
    Murugan, Raghavan
    Lamberty, Phillip E.
    Mahmud, Mujtaba
    Benedict, Neal J.
    Kellum, John A.
    Kane-Gill, Sandra L.
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (04) : 408 - 415